Enzon Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

ENZN 1.21 -0.06 (-4.72%)
price chart
Enzon Pharmaceuticals Inc Stock Upgraded (ENZN)
Compared to other companies in the Biotechnology industry and the overall market, ENZON PHARMACEUTICALS INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
Enzon Pharmaceuticals (ENZN) Is Today's Strong On High Volume Stock
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of ...
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) Still on Royalty-Driven Autopilot
Enzon Pharmaceuticals Inc (NASDAQ:ENZN, ENZN message board) published a 10-Q report for the quarter ended Mar. 31, 2015 last week, only a few weeks after ENZN hit a 52-week high on the charts, became overbought and subsided again.
5 NASDAQ Healthcare Stocks With The Highest ROA
Below are the top NASDAQ stocks in the healthcare sector in terms of return on assets. The trailing-twelve-month return on assets at Enzon Pharmaceuticals Inc (NASDAQ: ENZN) is 88.70 percent. Enzon Pharmaceuticals' revenue for the same period is ...
Enzon Pharmaceuticals, Inc. (ENZN) Ex-Dividend Date Scheduled for January ...
will begin trading ex-dividend on January 08, 2015. A cash dividend payment of $0.1 per share is scheduled to be paid on January 28, 2015.
Company Shares of Enzon Pharmaceuticals, Inc. Drops by -1.52%
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) has dropped 1.52% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 8.33% in the last 4 weeks.
Company Shares of Enzon Pharmaceuticals, Inc. Drops by -4.76%
Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) has lost 4.76% during the past week and dropped 8.4% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 4.38%.
Enzon Pharmaceuticals Moves Past the Tipping Point (ENZN)
If you're looking for a specific reason Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) is charging higher today, don't bother - you won't find one.
Stocks Flashing a Sell Signal: Netflix, Inc. (NASDAQ:NFLX), Enzon ...  Wall Street Observer
News Review: Enzon Pharmaceuticals Inc (NASDAQ:ENZN), Athersys, Inc ...  Market News Call
Enzon Pharmaceuticals (ENZN) Stock | Get Ready For Another Climb
Enzon Pharmaceuticals had a great week in the market last week. Unfortunately however, the stock is ... The company has been adding new prospects to its treatment repertoire and everything seems to be going well.
The Enzon Pharmaceuticals Pendulum is Poised to Swing the Other Way Again ...  SmallCap Network
Traders Alert - Enzon (ENZN), StemCells (STEM), Can (CANF), QUALCOMM ...  Investor Wired
Enzon Pharmaceuticals (ENZN) Weak On High Volume Today
Enzon Pharmaceuticals, Inc. engages in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular (wet) age-related macular degeneration; and CIMZIA for the treatment of ...